TICKERNERD
Menu
OPRXOPRXHealthcare · Health Information Services

OPRX Stock Forecast: OptimizeRx Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$8.72
−0.68% on the day

The 6 Wall Street analysts covering OptimizeRx Corp. hold a median 12-month price target of $11 — +26.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$132.5M
Ticker Nerd rank
83 / 100
Median analyst target
$11
Analysts covering
6
Total return, dividends reinvested
1W
+23.2%
1M
+33.5%
YTD
−28.9%
1Y
−50.4%
From 52W high
−59.8%
From 52W low
+92.1%
$5
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OPRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OptimizeRx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
90
Accruals
89
Value
84
Issuance
84
Size
70
Growth
68
Revisions
44
Volatility
26
Momentum
17

Quality (90): The business earns solid, repeatable profits on what it owns.

Momentum (17): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OPRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OPRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26OPRXHigh $18Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $9Median $11High $18

The green dot is the last close — the median target sits +26.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
13 May 2026B. Riley SecuritiesMaintainsBuy$11 → $10
13 May 2026Lake StreetMaintainsBuy$20 → $11
13 May 2026Stephens & Co.MaintainsEqual-Weight$10 → $7.00
13 May 2026StifelMaintainsBuy$17 → $14
6 Mar 2026B. Riley SecuritiesReiteratesBuy—
6 Mar 2026Lake StreetMaintainsBuy—
6 Mar 2026Roth CapitalMaintainsBuy—
6 Mar 2026Stephens & Co.MaintainsEqual-Weight—
6 Mar 2026StifelMaintainsBuy—
17 Nov 2025Stephens & Co.MaintainsEqual-Weight—
7 Nov 2025CitizensMaintainsMarket Outperform—
10 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
11 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
8 Aug 2025StifelMaintainsBuy—
9 June 2025StifelMaintainsBuy—
13 May 2025JMP SecuritiesMaintainsMarket Outperform—
13 May 2025StifelMaintainsBuy—
6 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
8 Jan 2025RBC CapitalDowngradeSector Perform—
24 Dec 2024B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OPRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.4%
Analysts raising
1
Analysts cutting
0
Fundamentals

OptimizeRx Corp. (OPRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.6×

Cheaper than 40% of US stocks

Price / sales
1.2×

Cheaper than 66% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
7.1×

Cheaper than 48% of US stocks

Growth & margins
Revenue growth (YoY)
−9.5%

Higher than 16% of US stocks

Earnings growth (YoY)
−9.5%

Higher than 26% of US stocks

Gross margin
75.2%

Higher than 87% of US stocks

Operating margin
2.0%

Higher than 49% of US stocks

Net margin
6.4%

Higher than 63% of US stocks

Returns & dividend
Return on equity
5.6%

Higher than 54% of US stocks

Return on assets
5.4%

Higher than 78% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OPRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
OPRXOptimizeRx Corp.$132.5M
83
LFMDLifeMD, Inc.$166.6M
30
HCATHealth Catalyst, Inc.$131.7M
52
AMWLAmerican Well Corp.$214.2M
80
SPOKSpok Holdings, Inc.$226.6M
62
CCLDCareCloud, Inc.$104.1M
71
DHDefinitive Healthcare Corp.$91.4M
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OptimizeRx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OPRX news & analysis

OptimizeRx Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026negative

OptimizeRx reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% year over year, while adjusted EBITDA came in at $4.9 million. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

Why it matters — The 30% revenue decline marks a sharp reversal from the prior year, making the company's ability to hit its reaffirmed full-year targets a key focus for investors.

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

OptimizeRx Corporation held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational performance for the quarter.

Why it matters — Investors and analysts following OptimizeRx would review the earnings call transcript for updates on the company's financial health, strategic direction, and outlook.

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 12 Aug 2026positive

OptimizeRx Corp. reported quarterly earnings of $0.16 per share for the second quarter, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share in the same quarter a year ago.

Why it matters — An earnings beat over the consensus estimate signals OptimizeRx outperformed analyst expectations for the quarter, which is relevant for investors tracking the company's results.

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth

GlobeNewsWire · 12 Aug 2026neutral

OptimizeRx Corp. announced that Andy D'Silva will become its next Chief Financial Officer and Heather Favazza will serve as Chief Accounting Officer, both effective January 1, 2027. The appointments are intended to support the company's next phase of growth.

Why it matters — An OPRX watcher would care because the new finance leadership appointments signal the company's preparation for its upcoming growth phase and management continuity.

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

GlobeNewsWire · 12 Aug 2026positive

OptimizeRx reported Q2 2026 revenue of $20.5 million, a net loss of $(0.7) million, and adjusted EBITDA of $4.9 million, while reaffirming its full-year 2026 revenue guidance of $95-$100 million and adjusted EBITDA guidance of $21-$25 million. The company also completed a debt refinancing with a $35 million traditional banking facility.

Why it matters — The debt refinancing and reaffirmed guidance signal improved financial stability and management's confidence in meeting its full-year targets.

FAQ

Frequently asked questions about OPRX stock

What is the OPRX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering OptimizeRx Corp. have a median 12-month price target of $11, with estimates ranging from $9 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OPRX stock a buy right now?

Of the 6 analysts covering OptimizeRx Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OptimizeRx Corp. 83 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OPRX?

As at 13 Aug 2026, OptimizeRx Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).

Will OPRX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +26.1% from the last close, and Ticker Nerd's factor model ranks OptimizeRx Corp. 83 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OPRX stock forecast for 2030?

No analyst covering OptimizeRx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $18 over the next 12 months.

How has OPRX stock performed over the past year?

OptimizeRx Corp. returned -50.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OptimizeRx Corp. do?

Optimizerx Corporation is a digital health platform provider focused on enhancing communication between life science organizations, healthcare providers, and patients. Its primary function is to deliver seamless integration of financial assistance, patient support, and clinical information into healthcare systems.

What is the latest news on OPRX?

The most recent item we track (MarketBeat, 13 Aug 2026): "OptimizeRx Q2 Earnings Call Highlights". OptimizeRx reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% year over year, while adjusted EBITDA came in at $4.9 million. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

Company

About OptimizeRx Corp.

Optimizerx Corporation is a digital health platform provider focused on enhancing communication between life science organizations, healthcare providers, and patients. Its primary function is to deliver seamless integration of financial assistance, patient support, and clinical information into healthcare systems. By operating within the healthcare technology sector, Optimizerx plays a pivotal role in enabling industry stakeholders to improve patient care outcomes, optimize the use of medications, and ultimately streamline the process of healthcare delivery. The company's innovative solutions facilitate the swift exchange of information, making healthcare more accessible and affordable for patients. In the broader financial market, Optimizerx Corporation represents the intersection of technology and healthcare, highlighting the growing trend towards digital solutions in enhancing healthcare delivery and patient engagement. As a publicly traded entity, it offers insights into the economic dynamics of the digital health space and its potential impact on the industry as a whole.

CEO Mr. Stephen L. Silvestro · 132 employees · United States · https://www.optimizerx.com